Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Working Capital Changes (2016 - 2025)

Coherus Oncology's Other Working Capital Changes history spans 13 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 201.98% year-over-year to $2.3 million; the TTM value through Dec 2025 reached -$10.3 million, down 121.44%, while the annual FY2025 figure was -$10.3 million, 121.44% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was $2.3 million at Coherus Oncology, up from -$15.1 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $8.7 million in Q4 2023 and bottomed at -$15.1 million in Q3 2025.
  • The 5-year median for Other Working Capital Changes is $203000.0 (2022), against an average of -$1.1 million.
  • The largest annual shift saw Other Working Capital Changes crashed 1702.76% in 2021 before it soared 201.98% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$8.4 million in 2021, then tumbled by 56.97% to -$13.2 million in 2022, then soared by 165.65% to $8.7 million in 2023, then plummeted by 126.14% to -$2.3 million in 2024, then skyrocketed by 201.98% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Other Working Capital Changes are $2.3 million (Q4 2025), -$15.1 million (Q3 2025), and $654000.0 (Q2 2025).